IBIO popped 3x March 26-28 and then retraced into a standard Fib level above which it has consolidated. The RSI lines are near to the 50 level and volumes are low. I can see where IBIO could go higher if interest and buying volumes rise. I will watch this for the same. Having profited heavily on the prior move, I would be happy to re-enter a long trade on IBIO.
VOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is a speculative long trade for this company with products to treat leukemia ( blood cancer). Price has crossed over the POC line of the volume profile and also completed an anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying volume...
AVTX popped on a big revenue beat on March 28th. It is now priced at about 3% of the ATH of last July. With the massive price jump came a 15X relative volume. The question is whether price has retraced into support and can rally again in the next market session. This remains to be seen. i will put AVTX on the top of my watch list and take a long trade if I...
LCTX on the weekly chart here has been falling since late 2021 and found support at the bottom of the high volume area of the volume profile and ranged between it and the POC line for the past 18 months. The is a high end clinically active biotechnology firm using stem cells to produce therapeutic cell lines . ( One experiment using the mammary glands of...
VTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and went parabolic on the next day and then faded while the moving averages and VWAP lines caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX did less than a full 0.5 retracement as a sign of strength. I will take a long...
JAN had earnings but I cannot find the report. It is trading with heavy volume and it shows in the price action. Price has pulled back in the after-market in a standard Fibonacci retracement. A pullback is appropriate here as price has gained 250% in a month. I see the pullback as healthy and JAN is now well positioned for another bullish continuation....
At some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
LVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma. It recently secured a collaboration agreement with Merck to assist in the clinical trials and the financial burdens it imposes in a quid pro quo related to a share of product margins in the future. On the 15-minute chart, LVTX burst out of a long-standing consolidation...
VERX on the 15 minute chart demonstrates printing a high tight bull flag pattern in its bullrun after the earnings report was a two line beat much like the one a quarter ago. VERX has impressed traders including this one who got in on the ride early. I will trade this like others recently with a similar pattern. I will hold during the consolidation and watch...
Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal...
MRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area...
LABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and...
RZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next...
SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been...
Introduction Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming...
Roivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report...
INBS crush earnings and went parabolic on an earnings beat. Basically, revenues fell but with belt-tightening and good CEO actions it bled less cash than expected. The tourniquet is working. The post-earnings pump was followed by a flush to the mid-Fib 0.5 support. Trader's got their reward and called it a weekend before lunch. The chop index fell into the...
RYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual...